Evaluation of Clinical Efficacy of Acute Cerebral Hemorrhage of Edaravone

Aim To evaluate the clinical efficacy of the treatment of acute cerebral hemorrhage of edaravone injection. Methods 86 patients with acute cerebral hemorrhage were randomly divided into observation group (n=46) and control group (n=40). The two groups were given conventional therapy,but the observation group added with intravenous infusion edaravone for four weeks. Neurologic impairment score,daily life activites ability score,hematoma volume and edema volume were observed. Results The differences of decrease of neurologic impairment score after 4 weeks treatment and the improvement of daily life activities ability score after 2 and 4 weeks treatment of the observation group were statistically significant compared with control group (P0.05); the differences of hematoma volume after 4 weeks treatment and the edema volume after 2 and 4 weeks treatment of the observation group were statistically significant compared with the control group (P0.05); the total efficiency of the observation group after 4 weeks treatment was higher than that of control group (P0.05). The occurrence rate of the two group adverse events were the same. Conclusion Edaravone is a safe and effective drug to the treatment of acute cerebral hemorrhage,which can improve neurologic impairment and the level of activities of daily life of the patients with acute cerebral hemorrhage,and promote hematoma absorption and restrain edema formation.